Corrigendum to “Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants” [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1](S0165032716304499)(10.1016/j.jad.2016.08.029)

D. Mischoulon, L. Hylek, A. S. Yeung, A. J. Clain, L. Baer, C. Cusin, D. F. Ionescu, J. E. Alpert, D. P. Soskin, M. Fava

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Corrigendum to “Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants” [J. Affect. Disord. 208 (2017, Jan. 15) 6-14, doi: 10.1016/j.jad.2016.08.029, Epub 2016 Oct. 1](S0165032716304499)(10.1016/j.jad.2016.08.029)'. Together they form a unique fingerprint.

Medicine & Life Sciences